MedTrace Logo

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

NCT00003241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of phenylacetate in treating children with recurrent or progressive brain tumors.

Conditions

Interventions

DRUG

phenylacetate

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Texas Children's Cancer Center

    lead OTHER

Principal Investigators

  • Lisa Bomgaars, MD · Texas Children's Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003241 on ClinicalTrials.gov